Can Fite BioPharma : Financial results for the six months ended June 30, 2023 and updates on its drug development programs and an unaudited interim condensed consolidated financial statements as of June 30, 2023. -Today at 09:30 am

UNITED STATES


SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549


FORM 6-K


Report of...

Related Keywords

Washington ,United States ,Israel ,Israeli ,American ,Motti Farbstein ,Kiryat Matalon ,Commission File Number ,Securities Exchange ,Fite Biopharma Ltd ,Foreign Private Issuer ,Securities Exchange Act ,Registration Statements ,Can Fite Biopharma ,Financial Review ,Extension Schema Document ,Extension Calculation Linkbase Document ,Extension Definition Linkbase Document ,Extension Label Linkbase Document ,Extension Presentation Linkbase Document ,Page Interactive Data File ,Executive Officer ,Can Fite Biopharma Ltd ,New Israeli Shekel ,Certain Terms ,American Depositary Shares ,Markets ,